Last reviewed · How we verify
Soolantra® Ivermectin cream 1%
Ivermectin is a macrocyclic lactone that binds to glutamate-gated chloride channels in parasites and may modulate innate immune responses in the skin.
Soolantra® (Ivermectin 1% cream) is a topical antiparasitic developed by Zydus Worldwide DMCC for the treatment of moderate to severe facial rosacea. It has completed Phase 3 trials and is not yet FDA-approved. The drug has shown good safety and efficacy in clinical trials, with common side effects including application site reactions.
At a glance
| Generic name | Soolantra® Ivermectin cream 1% |
|---|---|
| Sponsor | Zydus Worldwide DMCC |
| Drug class | Macrocyclic lactone antiparasitic / anti-inflammatory |
| Target | Glutamate-gated chloride channels; innate immune modulators |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Ivermectin works primarily by disrupting neurotransmission in parasites, causing paralysis and death. In rosacea, it is thought to reduce inflammation by suppressing innate immune activation, decreasing pro-inflammatory cytokine production, and potentially reducing the population of Demodex mites that may contribute to disease pathogenesis.
Approved indications
- Rosacea (inflammatory lesions)
Common side effects
- Skin irritation or burning
- Erythema
- Pruritus
- Dryness
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Soolantra® Ivermectin cream 1% CI brief — competitive landscape report
- Soolantra® Ivermectin cream 1% updates RSS · CI watch RSS
- Zydus Worldwide DMCC portfolio CI